Anti-Parkinsonian drugs are drugs which slow the progression or otherwise reduce the effects of Parkinson’s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. The major antiparkinson drugs are levodopa, dopamine-receptor agonists, amantadine, and the so-called COMT (catechol-O-methyltransferase) inhibitors, MAO-B (monoamine oxidase B) inhibitors, and muscarinic receptor antagonists.
